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ABSTRACT 
Rationale:  Low uptake of low-dose CT (LDCT) lung cancer screening, particularly by current 
smokers of a low socioeconomic position, compromises effectiveness and equity.   
Objectives: dŽĐŽŵƉĂƌĞƚŚĞĞĨĨĞĐƚŽĨĂ ‘ƚĂƌŐĞƚĞĚ ?ůŽǁďƵƌĚĞŶĂŶĚƐƚĞƉƉĞĚ ?ŝŶǀŝƚĂƚŝŽŶ
strategy versus control, on uptake of hospital-ďĂƐĞĚ ‘>ƵŶŐ,ĞĂůƚŚŚĞĐŬ ?ĂƉƉŽŝŶƚŵĞŶƚƐ
offering (LDCT) screening. 
Methods: A two-arm, blinded, between-subjects, randomised controlled trial.  2012 
participants were selected from 16 primary care practices using these criteria: i) aged 60-75, 
ii) recorded as a current smoker within the last seven years, iii) no pre-specified exclusion 
criteria contraindicating LDCT screening.  Both groups received a stepped sequence of pre-
invitation, invitation and reminder letters from their Primary Care Practitioner offering pre-
scheduled appointments.  The key manipulation was the accompanying leaflet. The 
intervention ŐƌŽƵƉ ?Ɛleaflet targeted psychological barriers and provided low burden 
information ?ŵŝŵŝĐŬŝŶŐƚŚĞĐŽŶĐĞƉƚŽĨƚŚĞh<DŝŶŝƐƚƌǇŽĨdƌĂŶƐƉŽƌƚ ?ƐĂŶŶƵĂůvehicle test 
 ? ‘DKdĨŽƌǇŽƵƌůƵŶŐƐ ? ? ? 
Measurements and Main Results: Uptake was 52.6%, with no difference between 
intervention (52.3%) and control (52.9%) groups in unadjusted (OR: 0.98, 0.82-1.16) or 
adjusted (aOR: 0.98, 0.82-1.17) analyses.  Current smokers were less likely to attend (aOR: 
0.70, 0.56-0.86) than former smokers.  Socioeconomic deprivation was significantly 
associated with lower uptake for the control group only (p<.01).  
Conclusions: The intervention did not improve uptake.  Regardless of trial arm, uptake was 
considerably higher than previous clinical and real world studies, particularly given the 
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sample were predominantly lower socioeconomic position smokers.  Strategies common to 
both groups, including a Lung Health Check approach, could represent a minimum standard.   
KEY WORDS (MeSH): Lung Neoplasms, Early Detection of Cancer, Behavioural Sciences, 
Socioeconomic Factors 
Abstract word count: 250 words 
Trial registration: This study was registered prospectively with the ISRCTN (International 
Standard Registered Clinical/soCial sTudy Number: ISRCTN21774741) on 23rd September 
2015 and the NIH ClinicalTrials.gov database (NCT02558101) on 22nd September 2015). 
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INTRODUCTION 
Lung cancer leads cancer mortality globally(1).  While tobacco control strategies are the 
primary means to reduce incidence, early diagnosis markedly increases five-year survival 
from 6% to 82% (stage IV vs. 1A non-small cell)(2).  Currently though, most (66%) diagnoses 
in the UK are made at an advanced stage(3).  The US National Lung Screening Trial (NLST; 
n=53,454) demonstrated that screening asymptomatic high-risk adults using low-dose 
computed tomography (LDCT) reduced the risk of mortality from lung cancer by 20% 
compared with chest X-ray(4).  Consequently, the US Preventive Services Task Force 
(USPSTF) recommended screening for high-risk adults.  dŚĞh< ?Ɛ National Screening 
Committee are awaiting the Dutch-Belgian trial NELSON ?Ɛfindings (n=15,822), but early data 
suggest a mortality benefit(5). 
Engaging those at high risk improves the risk-benefit ratio of screening.  However, 
enrolment into lung screening trials has been low (<5%)(6) and skewed towards those at 
lower risk.  Long-term smokers are overrepresented within lower socioeconomic position 
(SEP) communities, yet both current smoking status and low SEP are negatively associated 
with uptake(7,8) and positively associated with risk(9).  Indeed, ĚĞƐƉŝƚĞƚŚĞh^W^d& ?Ɛ
recommendation, just 1.9% of eligible, high-risk individuals have been screened in the 
US(10) ?ƚƚĞŶĚĂŶĐĞŽĨƉŝůŽƚ ‘>ƵŶŐ,ĞĂůƚŚŚĞĐŬ ?ƐĞƌǀŝĐĞƐin England has been relatively 
higher at 27% (Nottingham), 26% (Manchester), and 40% (Liverpool). Due to non-eligibility 
of some attenders, this translated to LDCT uptake by 13%, 14% and 9% respectively(11,12).   
Psychological barriers to participation were identified by research(13) that we undertook to 
inform the present intervention.  Together with existing studies, findings suggested smokers 
(compared with non-smokers) are more fatalistic about lung cancer, perceive treatment 
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efficacy as lower (13 W17), feel stigmatised (13,18), hold higher affective risk perceptions, 
and fear diagnosis(13,19).  Previous studies in colorectal cancer screening suggest tailoring 
leaflets to modify attitudinal barriers(20) may improve uptake(20 W22).  From a translational 
perspective, leaflets provide a low cost and scalable intervention.   
In addition to targeting psychological barriers, behavioural science theory such as the 
Precaution Adoption Process Model(23), proposes that different types of information are 
needed depending ŽŶĂŶŝŶĚŝǀŝĚƵĂů ?ƐƐƚĂƚĞŽĨengagement, decision-making and behaviour.  
A first-time invitation might primarily focus on engaging individuals in considering the offer 
using a low burden approach, with subsequent communication promoting informed choice 
and reducing practical barriers.  This stepped approach may be particularly important if the 
offer is anticipated to provoke fear, which can reduce receptivity (24,25), and for those with 
lower literacy, because information burden can reduce comprehension and promote 
distrust (23-26).  However to-date, recruitment methods for trials have been cognitively and 
practically demanding. 
Therefore, this trial primarily aimed to test the effect of targeted, stepped and low burden 
invitation materials ŽŶƵƉƚĂŬĞŽĨ ‘>ƵŶŐ,ĞĂůƚŚŚĞĐŬ ?ĂƉƉŽŝŶƚŵĞŶƚƐoffered in a real-world 
context.  The secondary aims were to explore whether the intervention materials affected 
informed decision-making outcomes, to gauge likely uptake of a national programme and to 
examine the feasibility of invitation via primary care.  Some results have been reported as 
an abstract(26). 
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METHODS 
Design  
A two-arm, blinded, between-subjects, randomised controlled trial design tested the effect 
of intervention invitation materials on uptake of a pre-scheduled Lung Health Check 
appointment, at which LDCT screening might be offered.  A protocol has been published(27) 
with potential overlap.  Eligible individuals were identified from primary care practices in 
London using electronic searches carried out between October 2015 and March 2017.   
Eligibility criteria 
The searches extracted individuals (n=147,015) aged 60-75 who had been recorded as a 
smoker since April 2010 (within 7 years of invitation).  This was the date smoking status 
became a Quality and Outcomes Framework (QoF) indicator to ensure completeness and 
identify current and recent ex-smokers.  The searches excluded individuals who had an 
active lung cancer diagnosis or metastatic cancer, were on the palliative care register, had 
undergone a recent CT thorax (<12 months), lacked capacity, had insufficient English or a 
comorbidity contraindicating screening or treatment.  Lists were then screened by GPs.  To 
avoid contamination, only one eligible individual per household was invited. 
Randomisation  
A web-based programme individually randomised participants (1:1) using permuted blocks 
to balance group allocation by practice.  Identifiable details were concealed during 
assignment, which was carried out by a blinded researcher.  Invited individuals were blind to 
the research nature at the invitation stage, to avoid undermining the primary outcome. 
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Intervention and control invitation materials 
Our invitation methods and evidence are published(13,27) and appended (Supplementary 
File 1).  Briefly, evidence-based methods were used for both invitation groups, including GP 
endorsement(21,28), pre-notification(29), reminders(30,31) and pre-scheduled 
appointments(32,33).  ThĞƐĐƌĞĞŶŝŶŐŽĨĨĞƌǁĂƐĨƌĂŵĞĚǁŝƚŚŝŶĂ ‘>ƵŶŐ,ĞĂůƚŚŚĞĐŬ ? ?All 
participants received the same postal invitation letters from their primary care practice: pre-
invitation letter, invitation letter with scheduled appointment, and reminder re-invitation 
letter with a second scheduled appointment (sent to non-responders >4 weeks after missed 
appointment).  The letters were identical with two exceptions: 1) ƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶŐƌŽƵƉ ?Ɛ
ůĞƚƚĞƌƐƌĞĨĞƌƌĞĚƚŽ ‘ĞǀĞƌƐŵŽŬĞƌƐ ?ǁŚĞƌĞĂƐƚŚĞĐŽŶƚƌŽůŐƌŽƵƉ ?ƐƌĞĨĞƌƌĞĚƚŽ ‘ĐƵƌƌĞnt and 
ĨŽƌŵĞƌƐŵŽŬĞƌƐ ? ?ĂŶĚ ? ?ƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶŐƌŽƵƉ ?ƐŝŶǀŝƚĂƚŝŽŶůĞƚƚĞƌŝŶĐůƵĚĞĚĂbullet-pointed 
summary of the Lung Health Check, including LDCT scan offer, on the reverse side.   
The key manipulation was the accompanying leaflet.  The control group received an 
information booklet mimicking  ‘ƚŚĞĨĂĐƚƐ ?ďŽŽŬůĞƚƐof NHS cancer screening programmes.  
The intervention group received an  ‘D ?K ?d ?ĨŽƌǇŽƵƌůƵŶŐƐ ?ůĞĂĨůĞƚ ?ĚĞƐŝŐŶĞĚƚŽƚĂƌŐĞƚ 
psychological barriers to attendance (fear, fatalism and stigma), to be low burden (sufficient 
for deciding to attend and consider the screening offer) and stepped (full information given 
at the appointment ƵƐŝŶŐƚŚĞĐŽŶƚƌŽůŐƌŽƵƉ ?ƐďŽŽŬůĞƚ, or available before via a website, 
phone or post).  Ŷ ‘D ?K ?d ? ?ŝƐĂŶĂŶŶƵĂůroadworthy test for vehicles and was a lay concept 
perceived to be analogous to a medical check-up preferred by patient and public 
involvement groups. 
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Lung Health Check appointment 
The appointments were run by research nurses and clinical trial practitioners at two London 
hospital outpatient clinics.  The appointment included a medical and smoking history to 
determine risk-based eligibility for the LDCT scan according to one of three criteria: i) NLST 
>30 pack year smoking history and still smoking or quit <15 years; ii) Prostate, Lung, 
Colorectal and Ovarian (PLCO) score >1.51%, or iii) Liverpool Lung Project (LLP) score >2.5%.  
Full information about the risks and benefits of screening was provided to all using the 
ĐŽŶƚƌŽůŐƌŽƵƉ ?ƐůĞĂĨůĞƚand supported by the nurse consultation.  A spirometry test and 
carbon monoxide (CO) reading were also carried out.  Participants self-reporting as current 
smokers or with a CO reading >10ppm were given accredited  ‘sĞƌǇƌŝĞĨĚǀŝĐĞ ?ŽŶƐŵŽŬŝŶŐ
(National Centre for Smoking Cessation and Training(34)) and randomised to an opt-out or 
opt-in referral intervention. 
 
Ethics 
Approval was granted by an NHS Research Ethics Committee (Reference:15/LO/1186).   
 
Primary outcome measure 
Attendance of the Lung Health Check appointment (% of those invited) to measure whether 
individuals could be engaged in considering a screening offer.   
 
Secondary outcome measures 
The pre-specified secondary endpoints in our statistical analysis plan (SAP) include 
comparison of uptake by demographic and smoking status sub-groups, uptake of LDCT 
screening for those eligible (and willingness among those ineligible), and informed decision-
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making outcomes.  ĂƚĂŽŶƉĂƌƚŝĐŝƉĂŶƚƐ ?ĞŶŐĂŐĞŵĞŶƚǁŝƚŚƚŚĞŝŶǀŝƚĂƚŝŽŶŵĂƚĞƌŝĂůƐǁĞƌĞĂůƐŽ
collected.  Further pre-specified endpoints are LDCT scan results, resource use, and 
psychological outcomes.   
 
Demographic data 
Pseudonymised data on age, sex, ethnicity and area-level socioeconomic deprivation (Index 
of Multiple Deprivation (IMD) score and rank), were collected from the primary care records 
of all those invited and again from attenders using self-report measures.  Attenders also 
reported their education level and marital status.  Hospital site of the screening offer was 
recorded. 
 
Smoking data  
Last recorded smoking status was extracted from primary care records (recoded as 
current/occasional, former and never).  Self-reported smoking status and smoking history 
were collected from attenders.  Smoking duration and pack-years were calculated by the 
research nurse in combination ǁŝƚŚƉĂƌƚŝĐŝƉĂŶƚƐ ?ƋƵŝƚŚŝƐƚŽƌŝĞƐ ? For current smokers, the 
ŶƵŵďĞƌŽĨƉƌĞǀŝŽƵƐ ‘ƐĞƌŝŽƵƐ ?ƋƵŝƚĂƚƚĞŵƉƚƐ, tobacco dependence(35) and perceived chances 
of quitting(36) were measured. 
 
Uptake data 
Secondary outcomes included uptake of LDCT screening for those eligible, and willingness to 
be screened for those ineligible. 
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Decision-making outcomes 
A self-complete paper questionnaire given at the appointment included adapted items from 
the Satisfaction with Decision (SWD) scale(37) and the low literacy version of the Decisional 
Conflict Scale (DCS)(38,39).  A further nine items measured conceptual and numerical 
knowledge of lung cancer screening; including original and adapted items(40).  Responses 
were dichotomised as correct vs. incorrect/not sure and summed. 
 
Engagement with the invitation leaflets 
Participants were asked whether they remembered, read and understood their respective 
leaflet, and whether they had beeŶ ‘ƵƐĞĨƵů ? ? ‘ĚŝĨĨŝĐƵůƚƚŽƵŶĚĞƌƐƚĂŶĚ ? ? ‘ŝŶĨŽƌŵĂƚŝǀĞ ? ? ‘ƚŽŽ
ĐŽŵƉůŝĐĂƚĞĚ ? ?ŽƌŚĂĚ ‘ƚŽŽůŝƚƚůĞŝŶĨŽƌŵĂƚŝŽŶ ? ?ZĞƐĞĂƌĐŚŶƵ ƐĞƐƌĂƚĞĚƉĂƌƚŝĐŝƉĂŶƚƐ ?
background knowledge of screening subjectively ĂƐ P ‘ŶŽŶĞ ? ? ‘ǀĞƌǇůŝƚƚůĞ ? ? ‘ŵŽĚĞƌĂƚĞ ? ? ‘ĨĂŝƌůǇ
ŐŽŽĚ ? ?ĂŶĚ ‘ǀĞƌǇĐŽŵƉƌĞŚĞŶƐŝǀĞ ?ŶĞĂƌƉĞƌĨĞĐƚ ? ? 
 
Statistical analyses 
Sample size 
Uptake for the control group was estimated to be 35% based on first-time uptake of the 
faecal occult blood test (FOBT) colorectal cancer screening programme in London within the 
two most deprived quintiles(41).  With a target sample size of 2000 participants randomised 
evenly into two arms, the study was statistically powered (at 90%) to detect a 7% increase in 
uptake using two-sided tests at the 5% significance threshold.  The 7% figure was based on 
ƐƚƵĚŝĞƐƚĞƐƚŝŶŐƚĂƌŐĞƚĞĚ ‘ƉƐǇĐŚŽ-ĞĚƵĐĂƚŝŽŶĂů ?ŝŶǀŝƚĂƚŝŽŶƐŝŶĐŽůŽƌĞĐƚĂůƐĐƌĞĞŶŝŶŐ(20,21) and 
considered a clinically meaningful benefit. 
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Primary analyses 
Data were analysed using IBM SPSS (v.25).  Analyses followed a prospectively registered SAP  
(DOI:10.17605/OSF.IO/HKEMM) and the trial protocol(27).  The primary outcome was 
analysed using an intention-to-treat approach (n=2012).  Attendance was compared by 
invitation group using logistic regression and a deviance chi-squared test for statistical 
significance.   
 
Secondary analyses 
Analyses tested for associations between demographic characteristics, smoking status, and 
attendance, using bivariate and then multivariable logistic regression models to calculate 
adjusted odds ratios (n=1970).  Study-specific quintiles for IMD rank were calculated 
because the sample was skewed toward above average deprivation. 
Logistic regression analyses then explored correlates of LDCT uptake among eligible 
participants.  The decision-making outcomes were compared by invitation group, using chi-
squared tests or T-tests.  &ŽƌĚĂƚĂĐŽůůĞĐƚĞĚĂĨƚĞƌĂƚƚĞŶĚĂŶĐĞ ? ‘ƉƌĞĨĞƌŶŽƚƚŽƐĂǇ ? ? ‘ŶŽƚƐƚĂƚĞĚ ?
Žƌ ‘ĚŽŶ ?ƚŬŶŽǁ ?ƌĞƐƉŽŶƐĞƐǁĞƌĞtreated as missing.   
 
RESULTS 
Characteristics of the invited sample 
The average age was 66.0 (SD:4.3), 53.7% were male, and the majority (79.7%) were from a 
White ethnic group (Table 1).  Overall, there was higher representation of ethnic minority 
groups compared with the general population (14%) but lower than in London (40%), likely 
due to the younger age structure and differences in s
11 
 
those invited (96.2%) were categorised within the most deprived (60.9%) or second most 
deprived (35.3%) IMD quintile.  Three quarters (74.5%) were current smokers.   
-Table 1- 
Primary analyses 
Uptake of the Lung Health Check 
Sixteen GP practices participated with a combined population of 147,015 patients (Figure 1).  
2012 individuals were randomised in equal numbers (n=1006) to the invitation groups.  Over 
half 52.6% (1058) attended their appointment (Table 1).   
Individuals predominantly attended the first appointment offered (40.3%), but 9.6% 
attended the second appointment offered with their reminder.  There was no response 
from 42.1%.  There was no statistically significant difference in uptake by hospital site 
(53.0% vs. 50.8%).  Most (94.9%) attenders enrolled.   
Near equal numbers from the intervention (52.3%) and control groups (52.9%: 526 vs. 532, 
respectively) attended.  In unadjusted analyses, there was no association between invitation 
group and uptake (OR: 0.98; 0.82-1.16; Table 2).    
-Figure 1ʹ 
Secondary analyses 
Correlates of uptake of the Lung Health Check 
Neither gender nor age were associated with uptake (Table 2).  Ethnicity was associated 
with uptake across groups (p<.001).  Compared with those of a White ethnic background, 
individuals of an Other ethnic background were more likely to attend (aOR: 2.34; 95% CI: 
1.30-4.20) and those with no recorded ethnic group were less likely to attend (aOR: 0.09; 
12 
 
0.04-0.19).  Higher deprivation was associated with lower uptake across study-specific IMD 
quintiles (p<.01).  Individuals categorised within the three least deprived study-specific 
quintiles had higher odds of attendance compared with those in the most deprived quintile 
(aOR: 1.62; 1.21-2.15 and aOR: 1.68; 1.26-2.25).  Current smokers were significantly less 
likely to attend than former smokers (aOR: 0.70; 0.56-0.86).   
When analyses of uptake were stratified by invitation group, there were again no 
associations with gender, age or hospital site.  For the control group, the same associations 
with Other (vs. White) ethnicity (aOR: 3.23; 1.28-8.14) and not stated ethnicity (aOR: 0.03; 
0.00-0.19) were observed.  Deprivation was significantly associated with increasingly lower 
odds of attendance across quintiles (p<.05).  For example, the odds of uptake for the least 
deprived quintile were nearly twice as high as those for the most deprived (aOR: 1.93; 1.28-
2.93).  Ethnicity was also associated with uptake for the intervention group (p<.001), with 
lower odds of uptake for those with no stated ethnic group (aOR: 0.15; 0.06-0.35).  
Conversely, deprivation did not significantly differentiate uptake in the intervention 
invitation group.   
Figure 2 presents the absolute percent uptake by study-specific IMD quintile and invitation 
group.  The gradient appears relatively less steep in the intervention group, with uptake 
relatively higher for the two most deprived quintiles in the intervention group (47.9% and 
53.5%) compared with the control group (42.8% and 49.7%), and relatively lower for the 
two least deprived quintiles (46.8% and 56.1% vs. 55.8% and 60.4%, respectively). 
-Table 2 and Figure 2ʹ 
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Smoking characteristics and eligibility for screening 
On average, attenders reported beginning smoking aged 17.9 (SD: 5.8) and accumulated a 
39.4 (SD: 25.0) pack-year history (Table 3).  Most current smokers had tried to quit 
previously (78.7%) and had low confidence in their chances of quitting (58.7%).  The 
majority (84.5%) were eligible for LDCT screening.  Among those ineligible (n=160), 
willingness to be screened was high (81.9%).   
-Table 3ʹ 
 
Uptake of the LDCT scan 
Most (91.2%) of those eligible chose to have the scan (Table 4).  Gender, age and marital 
status were not associated with LDCT uptake.  For ethnicity, Asian ethnicity predicted lower 
odds of uptake compared with White ethnicity (aOR: 0.09; 0.02-0.31), but there were few 
Asian participants (n=13).  There was no association with Black ethnicity, and too few non-
cases within the other ethnic groups.  Deprivation was not associated with LDCT uptake.  In 
unadjusted analyses, current smokers were less likely to opt for the LDCT scan than former 
smokers, but the association was not statistically significant in adjusted analyses (aOR: 0.52; 
0.27-1.01).  Invitation group did not affect the likelihood of LDCT uptake.  
-Table 4ʹ 
 
Engagement with the invitation leaflets 
A higher number of control participants (81.3%) remembered receiving their respective 
leaflet compared with the intervention group (64.1%, p<.001).  Intervention participants 
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understood more of their leaflet (p<.05) but there were no differences in background 
knowledge.  Supplementary File 2 presents further analyses. 
 
 
Decision-making outcomes 
There was no difference in mean scores for conceptual and numerical knowledge by 
invitation group (Supplementary File 2).  Across both groups, endorsement of the DCS was 
high (>76.2%) indicating low conflict.  Most participants reported awareness of the benefits 
of screening, knew which they valued, felt supported, and were clear about their choice (all 
>89.6%).  The risks were less well understood.  Fewer control participants reported that they 
knew what the risks were compared with intervention participants (76.2% vs. 83.2%, p<.05), 
but similar numbers knew which they valued (84.6% and 84.2%, respectively).  Decisional 
satisfaction was high across groups; both self-reported and nurse-rated (all >97.3%). 
 
DISCUSSION 
Uptake of the Lung Health Check was 53% which is an important finding in itself, 
considerably higher than previously observed.  The population was high-risk, with the 
majority eligible for LDCT screening.  The intervention made no difference to uptake overall 
or by smoking status, with uptake biased in favour of former (compared with current) 
smokers.  However, there was evidence that the targeted, stepped and low burden 
materials were relatively more effective at engaging the most deprived individuals. 
A major strength of this study is its ecological validity.  The design simulated a real-world 
service using practically feasible invitation methods via primary care, with the invited 
15 
 
sample unaware their attendance was under study.  Collecting individual-level demographic 
and smoking data provided a comprehensive understanding of non-responders.  A census-
derived, area-based measure of deprivation allowed national comparison, but is less 
sensitive to individual variation.  Moreover, the generalisability of these findings to affluent 
high-risk groups, a wider age range and ethnic minority groups may be limited.  We had 
complete data on most variables but there were 26 (1.3%) missing deprivation scores. 
Sensitivity analysis using multiple imputation made no difference to the findings. 
Fifty-three percent uptake is an encouraging figure compared with trials and pilot services 
to-date(11,12); especially given the invited sample was predominantly comprised of lower 
SEP current smokers.  In UKLS, interest from the most deprived quintile did not reach 
20%(9).  Indeed, attenders were high-risk, with 84% eligible for LDCT screening.  
Furthermore, this was a first-time invitation with no wider publicity or community 
engagement(11,12).  Uptake also compares favourably with first-time uptake of colorectal 
screening by Faecal Occult Blood Test (FOBT) in London (41%) and is on a par with national 
FOBT uptake (54%) when launched in 2006(41).  However, uptake is lower than current 
national figures for breast (71%) and cervical (72%) cancer, but seemingly not because men 
were less likely to attend. 
Finding a reduced socioeconomic gradient in uptake for the intervention group suggests 
that targeted and low burden invitation materials show promise for better engaging high-
risk individuals living in the most socioeconomically deprived areas.  Nevertheless, it was the 
control invitation strategy that achieved the highest uptake for the least deprived quintile.  
These results suggest that the intervention invitation approach may be the more equitable; 
holding potential for reducing inequalities and achieving a greater reduction in lung cancer 
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mortality by engaging those at highest risk.  Future research should examine the feasibility 
and acceptability of stratifying invitation materials by area-level deprivation. 
Related to this, intervention and control participants achieved similar decision-making 
outcomes, suggesting ƚŚĞ ‘ůŽǁinformation ďƵƌĚĞŶ ?ĐŽŵƉŽŶĞŶƚ did not compromise 
decision-making.  In fact, it was control participants who less frequently felt informed about 
ƚŚĞƌŝƐŬƐŽĨƐĐƌĞĞŶŝŶŐĚĞƐƉŝƚĞƌĞĐĞŝǀŝŶŐƚŚŝƐŝŶĨŽƌŵĂƚŝŽŶŝŶĂĚǀĂŶĐĞ ?KƵƌ ‘ůŽǁďƵƌĚĞŶ ?
component was informed by evidence that information burden can deter individuals with 
low literacy(43 W45) and that a third of non-participants in colorectal screening have not read 
the information booklet(46).  Moreover, information receptivity and comprehension may be 
adversely affected by a fearful emotional state(24,25), which a first-time lung screening 
invitation could provoke(13).  Perhaps the appointment was a better environment to 
achieve comprehension, with the research nurse ?ƐƐƵƉƉŽƌƚ and time to mentally adjust to 
the offer.  Alternatively, control participants may have paid less attention to the booklet at 
their appointment because the information was not novel.  Nevertheless, these findings 
suggest that providing detailed information with screening invitations may neither be 
sufficient for supporting informed choice nor an equitable invitation approach.  A low 
burden approach that builds up information in steps to full information provision during the 
appointment could be further tested for decision-making and inequalities in participation.   
The intervention had no effect on smoking-related inequalities, with uptake skewed in 
favour of former smokers as in previous trials(7 W9) and screening programmes for other 
cancer types(47 W50).  Research suggests that fatalism, fear and stigma are deep-rooted 
attitudes(13,17), which may be particularly resistant to change among current smokers.  
Alternatively, perhaps addiction-specific factors are more instrumental.  As this was a 
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multifactorial intervention with no process evaluation, we cannot draw conclusions about 
individual components.  It does however highlight there to be both independent and shared 
barriers to participation associated with lower SEP and current smoking status. 
A simple primary care record search effectively identified a largely screening-eligible 
population, suggesting invitation through primary care is feasible for a population-based 
programme, as well as a strategy likely to improve uptake.  Indeed, adopting the invitation 
methods common to both groups may optimise participation.  This includes a Lung Health 
Check approach, GP endorsement(21,23), pre-invitations(29), postal reminders(30), and 
scheduled appointments(34,51).  The reminder re-invitations offering a second scheduled 
appointment prompted uptake by a further 10%, suggesting that lowering practical 
demands helps non-responders overcome non-intentional barriers.  While offering 
scheduled appointments appears to have been effective, 47% of invited individuals did not 
attend which has resource implications.  We mitigated the impact by over-booking 
appointments and other strategies might include asking invitees to confirm attendance.  
Lessons could be learned from the h< ?ƐNHS Breast Cancer Screening Programme which 
sends timed appointments(30).  Overall, the likely effectiveness of the methods shared by 
both trial arms suggests that translating intention into action may be easier to achieve than 
changing attitudes.    
There remains a gap in knowledge of the most effective means of modifying psychological 
barriers to participation.  More foundational and experimental research is needed to isolate 
and test different approaches.  It is likely that a multi-pronged screening communication 
strategy would be needed as well as interventions at the wider healthcare system level, to 
ensure that the screening pathway optimises ŝŶĚŝǀŝĚƵĂůƐ ?screening experience.   
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Uptake of LDCT screening is likely to increase if offered as an organised Lung Health Check 
programme and individuals are invited via primary care.   It is possible to engage a high-risk, 
screening-eligible sample of lower SEP current smokers using feasible, population-based and 
low-cost methods.  A targeted, stepped and low burden invitation approach shows promise 
for reducing the social gradient in uptake by engaging individuals living in areas of highest 
deprivation, without compromised decision-making.  Further research is critical to 
understand how to further reduce inequalities; especially for current smokers. 
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Table 1   Sample characteristics of all those invited, overall and by invitation group  
 
 
 
 
 
 
 
 
 
 
 
 
 
 All 
(n=2012) 
Intervention 
(n=1006) 
Control 
(n=1006) 
Gender, % (n) 
     Female 
     Male 
 
46.3 (931) 
53.7 (1081) 
 
44.7 (450) 
55.3 (556) 
 
47.8 (481) 
52.2 (525) 
Age, mean (SD) 66.0 (4.3) 66.1 (4.3) 65.9 (4.3) 
Ethnicity, % (n) 
     Asian 
     Black 
     Mixed 
     White 
     Other 
     Not stated 
 
2.1 (42) 
9.6 (193) 
1.7 (34) 
79.7 (1604) 
2.9 (59) 
4.0 (80) 
 
2.3 (23) 
9.4 (95) 
1.4 (14) 
79.6 (801) 
3.1 (31) 
4.2 (42) 
 
1.9 (19) 
9.7 (98) 
2.0 (20) 
79.8 (803) 
2.8 (28) 
3.8 (38) 
National IMD quintile, % (n)  
     Quintile 1 (1-6496) most deprived 
     Quintile 2 (6497-12993) 
     Quintile 3 (12994-19489) 
     Quintile 4 (19490-25986) 
     Quintile 5 (25987-32482) least deprived 
     Missing 
 
60.9 (1226) 
35.3 (711) 
2.3 (47) 
0.1 (2) 
- 
1.3 (26) 
 
60.5 (609) 
35.4 (356) 
2.5 (25) 
0.1 (1) 
- 
1.5 (15) 
 
61.3 (617) 
35.3 (355) 
2.2 (22) 
0.1 (1) 
- 
1.1 (11) 
Smoking status, % (n)  
     Current smoker 
     Former smoker 
     Never smoked tobacco 
     Refused/Not stated 
     Missing 
 
74.5 (1499) 
24.7 (497) 
0.6 (13) 
0.1 (2) 
0.0 (1) 
 
76.2 (767) 
23.0 (231) 
0.8 (8) 
- 
- 
 
72.8 (732) 
26.4 (266) 
0.5 (5) 
0.2 (2) 
0.1 (1) 
Attendance, % (n) of all invited  
     Overall 
     Attended first appointment  
     Cancelled first appointment 
     Sent reminder (no response to first invitation) 
     Attended second (reminder) appointment 
     Cancelled second (reminder) appointment 
     No response to reminder invitation 
 
52.6 (1058) 
40.3 (811) 
5.0 (100) 
54.7 (1101) 
9.6 (194) 
2.9 (59) 
42.1 (848) 
 
52.3 (526) 
39.7 (399) 
4.6 (46) 
55.8 (561) 
9.4 (95) 
3.4 (34) 
42.9 (432) 
 
52.9 (532) 
41.0 (412) 
5.4 (54) 
53.7 (540) 
9.8 (99) 
2.5 (25) 
41.4 (416) 
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Figure 1  CONSORT trial flow diagram
Standardised search of 16 GP practice lists (n~147,015)  
Inclusion criteria: aged 60-75, recorded as smoker since April 2010 
Excluded (n= 145,003) 
i   Not meeting age or smoking inclusion 
criteria, or GP deemed individual 
unsuitable, or shared home address 
Assessed for LDCT scan (n=494) 
i Eligible and chose to have scan (n=386) 
i Eligible and chose not to have scan (n=30) 
i Not eligible to have scan (n=70) 
52.3% (n=526) 
i Participated in study (n=494) 
i Did not participate in study (n=32) 
Intervention group (n=1006) 
 
52.9% (n=532) 
i Participated in study (n=511) 
i Did not participate in study (n=21) 
Control group (n=1006) 
 
Assessed for LDCT scan (n=511) 
i Eligible and chose to have scan (n=384) 
i Eligible and chose not to have scan (n=44) 
i Not eligible to have scan (n=83) 
Allocation (n=2012) 
Consented to take part in LSUT (n=1005) 
Attended Lung Health Check (n=1058) 
Analysed of primary outcome (n=1006) 
i None excluded from analysis 
Analysis of primary outcome (n=1006) 
i None excluded from analysis 
Analysis 
Enrolment 
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Table 2  Frequencies and logistic regression analyses examining the correlates of uptake 
NOTE: aNo record of ethnic group in primary care; b2010 IMD rank quintile with cut-offs based on distribution in LSUT sample; c Cases with no 
IMD rank/score were excluded (n=26 in full sample); dNever smokers (n=13 in full sample) and refused/missing smoking status (n=3 in full 
sample) were excluded  
 All Intervention Control 
 Attended 
% (n) 
(n=2012) 
Unadjusted 
OR (95% CI) 
(n=2012) 
Adjusted 
OR (95% CI) 
(n=1970) 
Unadjusted 
OR (95% CI) 
(n=1006) 
Adjusted 
OR (95% CI) 
(n=983) 
Unadjusted 
OR (95% CI) 
(n=1006) 
Adjusted 
OR (95% CI) 
(n=987) 
Gender 
    Female 
    Male 
 
52.0 (479) 
53.4 (574) 
p=.557 
1.00 
1.05 (0.88, 1.26) 
p=.433 
1.00 
1.08 (0.90, 1.29) 
p=.828 
1.00 
0.97 (0.76, 1.25) 
p=.944 
1.00 
0.99 (0.76, 1.29) 
p=.290 
1.00 
1.14 (0.89, 1.47) 
p=.237 
1.00 
1.17 (0.90, 1.52) 
Age  p=.857 
1.00 (0.98, 1.02) 
p=.879 
1.00 (0.98, 1.02) 
p=.484 
0.99 (0.96, 1.02) 
p=.365 
0.99 (0.96, 1.02) 
p=.331 
1.02 (0.99, 1.05) 
p=.188 
1.02 (0.99, 1.05) 
Ethnicity 
    White 
    Asian 
    Black 
    Mixed 
    Other 
    Not stateda 
 
54.1 (864) 
52.6 (20) 
56.0 (107) 
36.4 (12) 
72.9 (43) 
8.9 (7) 
p<.001 
1.00 
0.85 (0.46, 1.57) 
1.11 (0.82, 1.49) 
0.47 (0.23, 0.95) 
2.29 (1.28, 4.10) 
0.08 (0.04, 0.18) 
p<.001 
1.00 
0.87 (0.45, 1.69) 
1.11 (0.82, 1.51) 
0.48 (0.24, 1.00) 
2.34 (1.30, 4.20) 
0.09 (0.04, 0.19) 
p<.001 
1.00 
1.13 (0.49, 2.60) 
1.09 (0.71, 1.68) 
0.35 (0.11, 1.12) 
1.82 (0.85, 3.92) 
0.15 (0.06, 0.35) 
p<.001 
1.00 
1.44 (0.56, 3.75) 
1.06 (0.68, 1.65) 
0.37 (0.11, 1.23) 
1.92 (0.89, 4.15) 
0.15 (0.06, 0.35) 
p<.001 
1.00 
0.61 (0.24, 1.53) 
1.12 (0.73, 1.71) 
0.56 (0.23, 1.38) 
3.07 (1.23, 7.66) 
0.02 (0.00, 0.17) 
p<.001 
1.00 
0.52 (0.20, 1.37) 
1.17 (0.76, 1.81) 
0.57 (0.23, 1.43) 
3.23 (1.28, 8.14) 
0.03 (0.00, 0.19) 
Study-specific deprivation 
quintileb 
    Quintile 1 (most deprived) 
    Quintile 2 
    Quintile 3  
    Quintile 4 
    Quintile 5 (least deprived) 
 
 
45.2 (179) 
51.6 (205) 
57.5 (234) 
51.3 (195) 
58.2 (227) 
 
p<.01c 
1.00 
1.29 (0.97, 1.70) 
1.63 (1.23, 2.15) 
1.27 (0.96, 1.68) 
1.65 (1.25, 2.19) 
 
p<.01 
1.00 
1.28 (0.96, 1.71) 
1.62 (1.21, 2.15) 
1.23 (0.92, 1.64) 
1.68 (1.26, 2.25) 
 
p=.154c 
1.00 
1.25 (0.84, 1.86) 
1.49 (1.00, 2.21) 
0.98 (0.66, 1.47) 
1.36 (0.91, 2.02) 
 
p=.100 
1.00 
1.28 (0.85, 1.92) 
1.49 (0.99, 2.24) 
0.96 (0.64, 1.45) 
1.44 (0.96, 2.17) 
 
p<.01c 
1.00 
1.31 (0.89, 1.93) 
1.77 (1.20, 2.62) 
1.63 (1.10, 2.42) 
2.01 (1.35, 2.99) 
 
p<.05 
1.00 
1.31 (0.87, 1.96) 
1.74 (1.16, 2.61) 
1.60 (1.06, 2.41) 
1.93 (1.28, 2.93) 
Smoking status  p<.001d p<.01 p<.05d p<.05 p<.01d p<.05 
    Former smoker 60.2 (299) 1.00 1.00 1.00 1.00 1.00 1.00 
    Current smoker 50.3 (754) 0.67 (0.55, 0.82) 0.70 (0.56, 0.86) 0.70 (0.52, 0.94) 0.72, 0.53, 0.97) 0.65 (0.49, 0.86) 0.68 (0.51, 0.92) 
Invitation group  p=.789 p=.843     
    Control 53.0 (529) 1.00 1.00 - - - - 
    Intervention 52.5 (524) 0.98 (0.82, 1.16) 0.98 (0.82, 1.18) - - - - 
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Figure 2  Uptake by study-specifica deprivation quintile (IMD) for each invitation group (n=2012) 
NOTE: a2010 IMD rank quintile with cut-offs based on distribution in LSUT sample 
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Table 3  Smoking characteristics of attenders consenting to LSUT and eligibility for 
LDCT 
NOTE: aNever smokers (n=4) and missing smokers (n=1) were excluded; bFormer smokers 
only (n=269) cFor participants reporting grams of tobacco per week, these were converted to 
number of cigarettes per day; dCurrent smokers only (n=709) 
 
 
 
 
 
 All 
(n=1000)a 
Intervention 
(n=492) 
Control 
(n=508) 
Age started smoking, mean (SD, range) 17.9 (5.8, 6-55) 17.9 (5.5, 7-55) 17.9 (6.1, 6-55) 
Age stopped smokingb, mean (SD, range) 59.4 (10.7, 0-75) 59.8 (10.4, 21-75) 59.1 (11.0, 0-75) 
Number of years smoked, mean (SD, range) 45.5 (9.5, 2-64) 45.6 (9.1, 2-64) 45.4 (9.9, 3-63) 
Pack years, mean (SD, range) 39.4 (25.0, 1-171) 38.0 (22.2, 1-128) 40.7 (27.5, 1-171) 
Usual daily cigarette consumptionc,d, % (n) 
    1 to 10 
    11 to 20 
    21 to 30 
    >31 
    Missing 
 
55.7 (395) 
33.3 (236) 
5.9 (42) 
2.3 (16) 
2.8 (20) 
 
55.3 (199) 
34.7 (125) 
5.3 (19) 
2.2 (8) 
2.5 (9) 
 
56.2 (196) 
31.8 (111) 
6.6 (23) 
2.3 (8) 
3.2 (11) 
Time to first cigaretted, % (n) 
    Within 5 minutes 
    6-30 minutes 
    31-60 minutes 
    >60 minutes 
    Missing 
 
16.5 (117) 
33.4 (237) 
16.8 (119) 
31.5 (223) 
1.8 (13) 
 
16.9 (61) 
33.9 (122) 
17.2 (62) 
31.1 (112) 
0.8 (3) 
 
16.0 (56) 
33.0 (115) 
16.3 (57) 
31.8 (111) 
2.9 (10) 
Nicotine dependence (HSI score)d, % (n)  
    Low dependence 
    Moderate dependence 
    High dependence 
    Missing 
 
38.9 (276) 
42.9 (304) 
14.5 (103) 
3.7 (26) 
 
38.6 (139) 
43.1 (155) 
15.3 (55) 
3.1 (11) 
 
39.3 (137) 
42.7 (149) 
13.8 (48) 
4.3 (15) 
Perceived chance of quittingd, % (n) 
    Very low/Low/Not very high 
    Quite high/Very high/Extremely high 
    Missing 
 
58.7 (416) 
38.5 (273) 
2.8 (20) 
 
56.9 (205) 
41.4 (149) 
1.7 (6) 
 
60.5 (211) 
35.5 (124) 
4.0 (14) 
Previous quit attemptsd, % (n) 
    None 
    1 to 5 
    >5 
    Missing 
 
20.3 (144) 
59.7 (423) 
19.0 (135) 
1.0 (7) 
 
21.7 (78) 
57.5 (207) 
20.0 (72) 
0.8 (3) 
 
18.9 (66) 
61.9 (216) 
18.1 (63) 
1.1 (4) 
Eligibility for LDCT scan, % (n) 84.5 (845) 84.6 (416) 83.4 (429) 
LDCT scan willingness (of ineligible), % (n) 
    Yes, definitely 
    Yes, probably 
    Probably not 
    Definitely not 
    Missing 
 
66.9 (107) 
15.0 (24) 
3.8 (6) 
3.8 (6) 
10.3 (17) 
 
71.8 (56) 
10.3 (8) 
1.3 (1) 
5.1 (4) 
11.5 (9) 
 
62.2 (51) 
19.5 (16) 
6.1 (5) 
2.4 (2) 
9.8 (8) 
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Table 4  Frequencies and logistic regression analyses examining the correlates of 
uptake of the LDCT scan among LDCT-eligible attenders 
NOTE: Missing data were excluded; a2010 IMD rank quintile with cut-offs based on 
distribution in LSUT sample 
 
 
 
 
 
 Attenders eligible for LDCT (n=845) 
 LDCT uptake 
% (n) 
Unadjusted 
OR (95% CI) 
Adjusted 
OR (95% CI) 
Overall 91.2 (770) - - 
Gender 
    Female 
    Male 
 
91.4 (342) 
91.1 (428) 
p=.846 
1.00 
0.95 (0.59,1.54) 
p=.979 
1.00 
1.01 (0.60, 1.68) 
Age 
 
 
- 
p=.275 
0.97 (0.92, 1.03) 
p=.267 
0.97 (0.91, 1.03) 
Marital status 
    Married/Cohabiting 
    Single/Separated/Divorced/Widowed 
 
92.2 (320) 
90.7 (449) 
p=.443 
1.00 
0.82 (0.50, 1.35) 
p=.394 
1.00 
0.79 (0.46, 1.36) 
Ethnicity 
    White  
    Asian 
    Black 
    Mixed 
    Other 
    Not stated 
 
91.3 (642) 
53.8 (7) 
92.7 (76) 
100.0 (8) 
97.1 (34) 
100.0 (3) 
p<.01 
1.00 
0.11 (0.04, 0.34) 
1.20 (0.50, 2.88) 
- 
- 
- 
p<.01 
1.00 
0.09 (0.02, 0.31) 
1.28 (0.52, 3.14) 
- 
- 
- 
Study-specific deprivation quintilea 
    Quintile 1 (most deprived) 
    Quintile 2 
    Quintile 3  
    Quintile 4 
    Quintile 5 (least deprived) 
 
88.2 (134) 
91.7 (154) 
95.6 (172) 
87.7 (136) 
92.7 (165) 
p=.074 
1.00 
1.48 (0.71, 3.08) 
2.89 (1.22, 6.85) 
0.96 (0.48, 1.91) 
1.71 (0.81, 3.61) 
p=.072 
1.00 
1.82 (0.75, 3.49) 
2.82 (1.18, 6.78) 
0.94 (0.46, 1.91) 
1.74 (0.80, 3.77) 
Smoking status 
    Former 
    Current (incl. occ) 
 
94.6 (211) 
90.0 (559) 
p<.05 
1.00 
0.51 (0.27, 0.97) 
p=.052 
1.00 
0.52 (0.27, 1.01) 
Invitation group 
    Control 
    Intervention 
 
89.7 (384) 
92.8 (386) 
p=.177 
1.00 
1.47 (0.91, 2.40) 
p=.075 
1.00 
0.63 (0.37, 1.05) 
